Renal Cancer - Results from #1520

Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. May 13, 2022

ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma. May 13, 2022

Quantifying Absolute Benefit for Adjuvant Treatment Options in Renal Cell Carcinoma: A Living Interactive Systematic Review and Network Meta-analysis. May 12, 2022

Impact of blood transfusion on survival after nephrectomy for localized or locally advanced renal cancer. May 12, 2022

Reproductive and external hormonal factors and the risk of renal cell cancer in the Netherlands Cohort Study. May 11, 2022

Developments in personalized therapy for metastatic renal cell carcinoma. May 11, 2022

A Randomized Ph2 Study of MEDI0680 in Combination With Durvalumab vs. Nivolumab Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma. May 10, 2022

Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities. May 10, 2022

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib. May 9, 2022

Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma. May 9, 2022

Cancer Mortality in People Receiving Dialysis for Kidney Failure: An Australian and New Zealand Cohort Study, 1980-2013. May 6, 2022

Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma. May 6, 2022

Surgical margins after partial nephrectomy as prognostic factor for the risk of local recurrence in pT1 RCC: a systematic review and narrative synthesis. May 5, 2022

Essential m6A Methylation Regulator HNRNPC Serves as a Targetable Biomarker for Papillary Renal Cell Carcinoma. May 5, 2022

ING4 Promotes Stemness Enrichment of Human Renal Cell Carcinoma Cells Through Inhibiting DUSP4 Expression to Activate the p38 MAPK/type I IFN-Stimulated Gene Signaling Pathway. May 4, 2022

Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. May 4, 2022

Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). May 3, 2022

Investigating miRNA-related Pathways Contributing to Kidney Cancer Pathogenesis. May 3, 2022

Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma. May 2, 2022

Guanylate-binding Protein 2 Expression Is Associated With Poor Survival and Malignancy in Clear-cell Renal Cell Carcinoma. May 2, 2022

Page 77 of 457